Magnetic Graphene Oxide Nanocarrier for Targeted Delivery of Cisplatin : A Perspective for Glioblastoma Treatment

dc.bibliographicCitation.firstPage76eng
dc.bibliographicCitation.issue2eng
dc.bibliographicCitation.volume12eng
dc.contributor.authorMakharza, Sami A.
dc.contributor.authorCirillo, Giuseppe
dc.contributor.authorVittorio, Orazio
dc.contributor.authorValli, Emanuele
dc.contributor.authorVoli, Florida
dc.contributor.authorFarfalla, Annafranca
dc.contributor.authorCurcio, Manuela
dc.contributor.authorIemma, Francesca
dc.contributor.authorNicoletta, Fiore Pasquale
dc.contributor.authorEl-Gendy, Ahmed A.
dc.contributor.authorGoya, Gerardo F.
dc.contributor.authorHampel, Silke
dc.date.accessioned2021-08-26T06:57:57Z
dc.date.available2021-08-26T06:57:57Z
dc.date.issued2019
dc.description.abstractSelective vectorization of Cisplatin (CisPt) to Glioblastoma U87 cells was exploited by the fabrication of a hybrid nanocarrier composed of magnetic γ-Fe2 O3 nanoparticles and nanographene oxide (NGO). The magnetic component, obtained by annealing magnetite Fe3 O4 and characterized by XRD measurements, was combined with NGO sheets prepared via a modified Hummer’s method. The morphological and thermogravimetric analysis proved the effective binding of γ-Fe2 O3 nanoparticles onto NGO layers. The magnetization measured under magnetic fields up to 7 Tesla at room temperature revealed superparamagnetic-like behavior with a maximum value of MS = 15 emu/g and coercivity HC ≈ 0 Oe within experimental error. The nanohybrid was found to possess high affinity towards CisPt, and a rather slow fractional release profile of 80% after 250 h. Negligible toxicity was observed for empty nanoparticles, while the retainment of CisPt anticancer activity upon loading into the carrier was observed, together with the possibility to spatially control the drug delivery at a target site. © 2019 by the authors. Licensee MDPI, Basel, Switzerland.eng
dc.description.versionpublishedVersioneng
dc.identifier.urihttps://oa.tib.eu/renate/handle/123456789/6599
dc.identifier.urihttps://doi.org/10.34657/5646
dc.language.isoengeng
dc.publisherBasel : MDPIeng
dc.relation.doihttps://doi.org/10.3390/ph12020076
dc.relation.essn1424-8247
dc.relation.ispartofseriesPharmaceuticals 12 (2019), Nr. 2eng
dc.rights.licenseCC BY 4.0 Unportedeng
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/eng
dc.subjectCisplatineng
dc.subjectGlioblastomaeng
dc.subjectGraphene oxideeng
dc.subjectMaghemiteeng
dc.subjectMagnetic targetingeng
dc.subject.ddc610eng
dc.titleMagnetic Graphene Oxide Nanocarrier for Targeted Delivery of Cisplatin : A Perspective for Glioblastoma Treatmenteng
dc.typearticleeng
dc.typeTexteng
dcterms.bibliographicCitation.journalTitlePharmaceuticalseng
tib.accessRightsopenAccesseng
wgl.contributorIFWDeng
wgl.subjectMedizin, Gesundheiteng
wgl.typeZeitschriftenartikeleng
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Magnetic graphene oxide nanocarrier for targeted delivery of cisplatin_A perspective for glioblastoma treatment.pdf
Size:
3.63 MB
Format:
Adobe Portable Document Format
Description:
Collections